Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 86 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/19/2006


1.		Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Renal Cell Carcinoma --- A Modified Group C Study (Summary Last Modified 04/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				16 and over								NCI-C87-0001 AECM-8706153, CHNMC-COH-7077, CMGH-8756-S-87A, CWRCC-0987188, DUMC-7988710, FCCC-88982, IDB-MGC-RENAL/RAND, JHOC-87092507, MDA-DM-87059, UAC-345, UCCRC-4998, UPCC-1887, UUMC-2056, VRCC-CHRMS-8831, WSU-C-70387, YALE-HIC-4454, C87-0001

Last Modified: 10/19/2006


2.		Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Malignant Melanoma --- A Modified Group C Study (Summary Last Modified 04/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				16 and over								NCI-C87-0002 AECM-8706152, CHNMC-COH-7075, CMGH-8755-S-87A, CWRCC-0787137, DUMC-7958710, IDB-MGC-MEL/RAND, JHOC-87092508, MDA-DM-87056, UAC-343, UCCRC-4985, UKMC-8800110, UPCC-1687, UUMC-2055, VRCC-CHRMS-8832, WSU-C-70487, YALE-HIC-4455, C87-0002

Last Modified: 1/1/1988


3.		Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Carcinoma of the Colon (Summary Last Modified 01/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70								UCCRC-4973A NCI-V87-0310

Last Modified: 1/1/1988


4.		Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Malignant Melanoma (Summary Last Modified 01/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70								UCCRC-4973B NCI-V87-0311

Last Modified: 4/26/2007


5.		Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Renal Cell Carcinoma (Summary Last Modified 01/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 70								UCCRC-4973C NCI-V87-0312

Last Modified: 11/1/1990


6.		Phase II/III Adoptive Immunotherapy for Metastatic Renal Cell Carcinoma: Systemic IL-2 plus IL-2-Activated/Periodate-Treated Cells (Summary Last Modified 11/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				21 to 70								NYH-1088-350CRC NCI-V88-0417

Last Modified: 4/1/1991


7.		Phase III Prospectively Randomized Study of Adoptive Immunotherapy with High-Dose Recombinant IL-2 Administered Alone vs High-Dose Recombinant IL-2 Administered in Conjunction with Systemic Administration of LAK Cells in Patients with Advanced Cancer (Summary Last Modified 04/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				any age				NCI				NCI-86-C-46 NCI-T86-0097N, T86-0097

Last Modified: 10/1/1989


8.		Phase III Prospectively Randomized Study of Surgery Alone vs Surgery plus Adjuvant Immunotherapy with High-Dose Recombinant IL-2 vs Surgery plus Adjuvant High-Dose Recombinant IL-2 in Conjunction with the Systemic Administration of LAK Cells in Patients with Stage II Melanoma (Summary Last Modified 10/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				any age				NCI				NCI-86-C-50 NCI-T86-0099N, T86-0099


9.		Phase III Prospective Randomized Study of Adjuvant Immunotherapy with High-Dose Recombinant IL-2/LAK Cells in Patients with Locally Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				NCI-86-C-157A NCI-T86-0247N, T86-0247

Last Modified: 12/1/1990


10.		Phase III Randomized Study of Infusional IL-2 Alone vs with Adoptive Immunotherapy Using IL-2-Pulsed Mononuclear Peripheral Blood Cells in Patients with Advanced Renal Cancer (Summary Last Modified 12/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over								NBSG-9007 NCI-V90-0143

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute